Helus Pharma Completes Phase 3 HLP003 Enrollment in MDD
NEW YORK and TORONTO, Aug. 14, 2026 Helus Pharma is advancing its late-stage clinical development strategy for novel serotonergic...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK and TORONTO, Aug. 14, 2026 Helus Pharma is advancing its late-stage clinical development strategy for novel serotonergic...
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
NEW YORK, July 6, 2026 AtaiBeckley Inc. announced that the final patient has been dosed in Elumina, its international...
TOKYO, Japan & PRINCETON, N.J., June 26, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc....
BOSTON, June 8, 2026 PureTech Health and its Founded Entity Seaport Therapeutics announced positive results from the multiple-ascending dose...
BOSTON, Feb. 20, 2026 — Seaport Therapeutics announced new findings from a comprehensive meta-analysis examining how clinical trial design...
